← All trials
NCT02462304
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2015
- Primary completion
- Jun 1, 2017
- Completion date
- Dec 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- The University of Hong KongLead sponsor
- Nagoya City UniversityCollaborator
- Kyoto UniversityCollaborator
- Osaka Medical CollegeCollaborator
- Kyushu UniversityCollaborator
- Kyorin UniversityCollaborator
- Inje UniversityCollaborator
- Korea UniversityCollaborator
- Yamagata UniversityCollaborator
- Chungnam National UniversityCollaborator
- Kyung Hee UniversityCollaborator
- Asahikawa Medical CollegeCollaborator
- University of FukuiCollaborator
- Eguchi Eye ClinicCollaborator
- Hokkaido UniversityCollaborator
- Sun Cheon Hyang UniversityCollaborator
- Tokyo Medical UniversityCollaborator
- Yeungnam UniversityCollaborator
- Kyungpook UniversityCollaborator
- The University of Hong KongOverall official - principal investigator
- The University of Hong KongReponsible party - principal investigator
- National University of SingaporeCollaborator
- University of NagasakiCollaborator
- Pusan National UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.